Complement activation plays a key role in the side-effects of rituximab treatment
- PMID: 11843813
- DOI: 10.1046/j.1365-2141.2001.03166.x
Complement activation plays a key role in the side-effects of rituximab treatment
Abstract
Treatment with rituximab, a chimaeric anti-CD20 monoclonal antibody, can be associated with moderate to severe first-dose side-effects, notably in patients with high numbers of circulating tumour cells. The aim of this study was to elucidate the mechanism of these side-effects. At multiple early time points during the first infusion of rituximab, complement activation products (C3b/c and C4b/c) and cytokines [tumour necrosis factor alpha (TNF-alpha), interleukin 6 (IL-6) and IL-8] were measured in five relapsed low-grade non-Hodgkin's lymphoma (NHL) patients. Infusion of rituximab induced rapid complement activation, preceding the release of TNF-alpha, IL-6 and IL-8. Although the study group was small, the level of complement activation appeared to be correlated both with the number of circulating B cells prior to the infusion (r = 0.85; P = 0.07) and with the severity of the side-effects. We conclude that complement plays a pivotal role in the pathogenesis of side-effects of rituximab treatment. As complement activation can not be prevented by corticosteroids, it might be relevant to study the possible role of complement inhibitors during the first administration of rituximab.
Similar articles
-
Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8).Blood. 1999 Oct 1;94(7):2217-24. Blood. 1999. PMID: 10498591 Clinical Trial.
-
Pathogenic study of anti-CD20 infusion-related severe refractory shock in diffuse large B-cell lymphoma.Leuk Lymphoma. 2006 Jan;47(1):111-5. doi: 10.1080/10428190500254752. Leuk Lymphoma. 2006. PMID: 16321834
-
Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.Haematologica. 2002 Jan;87(1):33-43. Haematologica. 2002. PMID: 11801463
-
Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma.Drugs. 2007;67(3):333-50. doi: 10.2165/00003495-200767030-00002. Drugs. 2007. PMID: 17335294 Review.
-
Rituximab.Drugs. 1999 Jul;58(1):79-88; discussion 89-90. doi: 10.2165/00003495-199958010-00009. Drugs. 1999. PMID: 10439931 Review.
Cited by
-
Rituximab-induced tumor progression: does it really happen?Med Oncol. 2004;21(2):205-6. doi: 10.1385/MO:21:2:205. Med Oncol. 2004. PMID: 15299193
-
Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy.Front Immunol. 2018 Jan 4;8:1751. doi: 10.3389/fimmu.2017.01751. eCollection 2017. Front Immunol. 2018. PMID: 29379493 Free PMC article. Review.
-
Systemic and local evidence for complement involvement in chronic spontaneous urticaria.Clin Transl Allergy. 2021 Jul 3;11(5):e12011. doi: 10.1002/clt2.12011. eCollection 2021 Jul. Clin Transl Allergy. 2021. PMID: 34262691 Free PMC article.
-
Transient wheal attack corresponding to the tumor lesions of primary cutaneous diffuse large B cell lymphoma, leg type after successive rituximab treatment.Case Rep Dermatol. 2014 Sep 11;6(3):218-21. doi: 10.1159/000367936. eCollection 2014 Sep. Case Rep Dermatol. 2014. PMID: 25408649 Free PMC article.
-
Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium.Clin Exp Immunol. 2015 Sep;181(3):385-400. doi: 10.1111/cei.12652. Epub 2015 Jul 2. Clin Exp Immunol. 2015. PMID: 25959571 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous
